medigraphic.com
ISSN 2594-1526 (Digital)
ISSN 0028-3746 (Impreso)
Antes Revista del Instituto Nacional de Enfermedades Respiratorias

 Ver anteriores al 2010

2006, Número S4

<< Anterior Siguiente >>

Neumol Cir Torax 2006; 65 (S4)


Test de reactividad vascular pulmonar

Robledo PJC, Rosas RMJR, Campos CR, Morales BJE

Idioma: Español
Referencias bibliográficas: 51
Paginas: 43-50
Archivo PDF: 76.33 Kb.


RESUMEN

La hipertensión arterial pulmonar se define como la presencia de presión pulmonar media › 25 mmHg en reposo o 30 mmHg durante el ejercicio. El incremento de la presión pulmonar puede ser el resultado de la elevación en la resistencia vascular pulmonar o del flujo sanguíneo pulmonar; sin embargo, aún teniendo un incremento muy significativo en el flujo sanguíneo pulmonar rara vez produce una elevación grave de la presión pulmonar a menos que coexistan cambios patológicos vasculares. El cateterismo cardiaco derecho es el estándar de oro y debe realizarse en todos aquellos pacientes que se están estudiando por hipertensión arterial pulmonar, no sólo confirma la presencia de la enfermedad, sino también es útil en el diagnóstico diferencial, evalúa la severidad de la hipertensión y sobre todo es posible determinar un factor pronóstico a través de la respuesta que se obtiene durante la administración de vasodilatadores. Los vasodilatadores que en la actualidad se utilizan durante la prueba de reactividad vascular pulmonar son adenosina, prostaciclina o análogos y óxido nítrico. Los pacientes considerados con respuesta son aquéllos en los cuales hay una disminución en la presión pulmonar media ≤ 40 mmHg, o cuando menos del 10% de la misma; la prueba es útil para justificar el efecto benéfico de bloqueadores de canales de calcio por tiempo prolongado.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Griffith GC, Cosby RS, Levinson DC. Cardiac catheterization in adult congenital disease. A preliminary report. Calif Med 1950; 72: 431-41.

  2. Gaine SP, Rubin LJ. Primary pulmonary hypertension. Lancet 1998; 352: 719-25.

  3. Lupi E, Bialostozky D, Sobrino A. The role of isoproterenol in pulmonary artery hypertension of unknown etiology (primary): short and long term evaluation. Chest 1981; 79: 292-6.

  4. Lupi E, Sandoval J, Seoane M, Bialostozky D. The role of hydralazina therapy for pulmonary arterial hypertension of unknown cause. Circulation 1982; 65: 645-50.

  5. Seoane M, Vallejo J, Sandoval J, Lupi E. Efectos de la nifedipina en pacientes con enfermedad pulmonar obstructiva crónica inestable. Arch Inst Cardiol Mex 1986; 56: 109-16.

  6. Pearl R, Rosenthal MH, Schroeder JS, Ashton JP. Acute hemodynamic effects of nitroglycerin in pulmonary hypertension. Ann Int Med 1983; 99: 9-13.

  7. Rubin LJ, Groves BM, Reeves JT. Prostacyclin induced acute pulmonary vasodilation in pulmonary hypertension. Circulation 1982; 66: 334-8.

  8. Groves BM, Badesh DB, Donellan K. Acute hemodynamic effects of iloprost in primary (unexplained) pulmonary hypertension. Semin Resp Crit Care Med 1994; 15: 230-7.

  9. Leier C, Bambach D, Thompson M, Cattaneo S, Goldberg R, Unverferth D. Central and regional hemodynamic effects of intravenous isosorbide dinitrate, nitroglicerin and nitroprusside in patients with congestive heart failure. Am J Cardiol 1981; 48: 1115-23.

  10. Michelakis E, Tymchak W, Lien D, Webster L, Hashimoto K, Archer S. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension. Comparison with inhaled nitric oxide. Circulation 2002; 105: 2398-2403.

  11. Rubin L, Badesh D. Evaluation and management of the patient with pulmonary arterial hypertension. Ann Intern Med 2005; 143: 282-92.

  12. Cáneva JO, Osses JM. Diagnóstico de la hipertensión pulmonar primaria. Arch Bronconeumol 2002; 38: s16-s23.

  13. Sznajer JI, Zveibel FR, Bitterman H. Central venous catheterization. Failure and complications rates by three percutaneous approaches. Arch Inter Med 1986; 146: 259-64.

  14. Guillinta P, Peterson KL, Yehuda O. Cardiac catheterization techniques in pulmonary hypertension. Cardiol Clin 2004; 22: 401–15.

  15. Groves B, Badesh D. Cardiac catheterization of patients with pulmonary hypertension. In: Peacok A, Rubin L. Pulmonary Circulation, Chapman and Hall Medical Edit 2004; 212-32.

  16. Morales-Blanhir JE, Santos S, de Jover L, Sala E, Pare C, Roca J, Rodríguez- Roisin R, Barberà JA. Clinical value of vasodilator test with inhaled nitric oxide for predicting long-term response to oral vasodilators in pulmonary hypertension. Respir Med 2004; 98: 225-34.

  17. Galiè N, Ussia G, Pasarelli P, Parlangeli R, Branzi A, Magnani B. Role of pharmacologic test in the treatment of primary pulmonary hypertension. Am J Cardiol 1995; 75: 55a-62a.

  18. Barst RJ, McGoon M, Torbicki A, Gaine S. Diagnosis and differential Assessment of Pulmonary Arterial Hypertension. J Am Coll Cardiol 2004; 43: 40S-7S.

  19. Mc Laughlin V, Presberg WK, Doyle R, Ahearn G. Prognosis of pulmonary arterial hypertension. ACCP Evidence-Based Clinical Practice Guidelines. Chest 2004; 126: 78S-92S.

  20. Lupí E, Seoane M, Sandoval J, Gómez A. Hemodynamic effect of hydralazine in interstitial lung disease patients with cor pulmonale. Immediate and short-term evaluation at rest and during exercise. Chest 1985; 87: 564-73.

  21. Sandoval J, Bauerle Otto, Palomar A, Gómez Arturo, Martínez-Guerra ML. Survival in primary pulmonary hypertension. Validation of a prognostic equation. Circulation 1994; 89: 1733-44.

  22. Sandoval J, Suárez J, López ES, Robledo PJ. Utilidad de la adenosina para identificar respuesta vasodilatadora pulmonar en hipertensión arterial pulmonar primaria. Arch Inst Cardiol Mex 1995; 65: s203.

  23. McGoodon Michael D. The assessment of pulmonary Hypertension. Clinics in Chest Medicine 2001; 22: 504-5.

  24. Kneussi MP, Lang IM, Brenot FP. Medical management of primary pulmonary hypertension. Eur Respir J 1996; 9: 2401-9.

  25. Galiè N, Seeger W, Naeije R, Simonneau G, Rubin L. Comparative analysis of clinical Trials, and Evidence-Based Treatment Algorithm in Pulmonary Arterial Hypertension. J Am Coll Cardiol 2004; 43: 81S-88S.

  26. Badesch DB, Abman SH, Ahearn GS, McLaughlin VV. Medical therapy for pulmonary arterial hypertension. ACCP Evidence-Based Clinical Practice Guidelines. Chest 2004;1 26: 35S-62S.

  27. Inbar S, Schrader B, Kaufmann E, Vestal R, Rich S. Effects of adenosine in combination with calcium channel blockers in patients with primary pulmonary hypertension. J Am Coll Cardiol 1993; 21: 413-8.

  28. Lupi E, Seoane M, Sandoval J, Martínez W. La hidralazina y el transporte de oxígeno en la neumopatía intersticial y obstructiva pulmonar crónica. Arch Inst Cardiol Mex 1987; 57: 357-61.

  29. Beltran M, Sandoval J, Seoane M, Lupi E. Diez años de experiencia con el uso de vasodilatadores en el tratamiento de la hipertensión arterial pulmonar primaria (1977-87). Arch Inst Cardiol Mex 1988; 58: 281-91.

  30. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med. 2004; 351: 1425–36.

  31. Sitbon O, Humbert M, Jagot JL, Taravella O, Fartoukh M, Parent F, Hervé P, Simonneau G. Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. Eur Respir J 1998; 12: 265–70.

  32. Sitbon O, Humbert M, Jaïs X, Ioos V, Hamid A, Provencher S, Garcia G, Parent F, Hervé P, Simonneau G. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005; 111: 3105-11.

  33. Schrader BJ, Inbard S, Kaufmann L, Rich Stuart. Comparison of the Effects of adenosine and nifedipina in pulmonary Hypertension. J Am Coll Cardiol 1992; 19: 1060-4.

  34. Nootens M, Schrader B, Kauffman E, Rich S. Comparative acute effects of adenosine and prostacyclin in primary pulmonary hypertension. Chest 1995; 107: 54-7.

  35. Reeves J, Groves B, Weir EK. Adenosine and selective reduction of pulmonary vascular resistance in primary pulmonary hypertension. Circulation 1991; 84: 1437-9.

  36. Morgan JM, McCormack DG, Griffiths MJ, Morgan CJ, Barnes PJ, Evans TW. Adenosine as a vasodilator in primary pulmonary hypertension. Circulation 1991; 84: 1145-49.

  37. Haywood GA, Sneddon JF, Bashir Y, Jenninson SH, Gray HH, McKenna WJ. Adenosine infusion for the reversal of pulmonary vasoconstriction in biventricular failure. A good test but a poor therapy. Circulation 1992; 86: 896-902.

  38. Rubin LJ, Groves BM, Reeves JT, et al. Prostacyclin induced acute pulmonary vasodilation in pulmonary hypertension. Circulation 1982; 66: 334-8.

  39. Groves BM, Rubin LJ, Frosolono MF, et al. A comparison of the hemodinamic effects of prostacyclin and hydralazine in primary pulmonary hypertension. Am Heart J 1985; 110: 1200-4.

  40. Barst RJ, Rubin L, Long WA, et al for the Primary Pulmonary Hypertension Study Group. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996; 334: 296-301.

  41. Badesh DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized controlled trial. Ann Int Med 2000; 132: 425-34.

  42. Olschewsky H, Walmrath D, Schermuly R, et al. Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Ann Int Med 1996; 124: 820-4.

  43. Hoeper MM, Olschewsky H, Ghofrani HA, et al. A comparison of the acute hemodynamics effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. J Am Coll Cardiol 2000; 35: 179-82.

  44. Opitz CF, Wensel R, Bettmann M, et al. Assessment of the vasodilator response in primary pulmonary hypertension. Comparing prostacyclin and iloprost administered by either infusion or inhalation. European Heart Journal 2003; 24: 356–65.

  45. Fruhwald F, Kjellstro B, Perthold W, et al. Continuous hemodynamic monitoring in pulmonary hypertensive patients treated with inhaled iloprost Chest 2003; 124: 351–59.

  46. Wensel R, Opitz F, Ewert R, et al. Effects of iloprost inhalation on exercise capacity and ventilatory efficiency in patients with primary pulmonary hypertension. Circulation. 2000; 101: 2388-92.

  47. Blumberg F, Riegger G, Pfeifer M. Hemodynamic effects of aerosolized iloprost in pulmonary hypertension at rest and during exercise. Chest 2002; 121: 1566–71.

  48. Pepke-Zaba J, Higenbottam TW, Dinh-Xuan AT, et al. Inhaled nitric oxide as a cause of selective pulmonary vasodilation in pulmonary hypertension. Lancet 1991; 338: 1173-4.

  49. Ricciardi MJ, Knigth BP, Martínez FJ. Inhaled nitric oxide in primary pulmonary hypertension. A safe and effective agent for predicting response to nifedipine. J Am Coll Cardiol 1998; 32: 1068-73.

  50. Krasuski RA, Wang A, Harrison JK, Tapson VF, Bashore TM. The response to inhaled nitric oxide in patients with pulmonary artery hypertension is not masked by baseline vasodilator use. Am Heart J 2005; 150: 725-8.

  51. Williamson DJ, Hayward C, Macdonald PS. Acute Hemodynamic responses to inhaled nitric oxide in patients with limited scleroderma and isolated pulmonary hypertension. Circulation 1996; 94: 477-82.




2020     |     www.medigraphic.com